Authors
Loading...
Prospective analysis shows motixafortide improves CD34+ yield in poor mobilizers compared to plerixafor, despite increased adverse reactions.
Sarhan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: